Abstract: A DC power supply circuit outputs an output voltage, which varies with an input voltage. The output voltage therefore occasionally deviates from a normal output voltage range although the DC power supply circuit is normal. However, the DC power supply circuit converts the input voltage in a predetermined relation between the input voltage and the output voltage. When the output voltage of the DC power supply circuit deviates from a predetermined normal output voltage range, a determination circuit determines that the DC power supply circuit is abnormal when the input voltage and the output voltage of the DC power supply circuit are not in the predetermined relation. It is thus prevented that the DC power supply circuit is erroneously determined to be abnormal although operating normally. As a result, it is possible to eliminate erroneous determination in determining the operation state itself.

Abstract: [Problem] To provide a novel compound that exhibits an agonistic effect on dopamine D2 receptors. [Solution] The present invention provides a compound represented by the general formula (I): in which R1 is C1-6 alkyl or the like; R2 is hydrogen or the like; R3 and R4 are each hydrogen, C1-6 alkyl, R10R11N—C1-6 alkyl, aralkyl, or the like; R5 and R6 are hydrogen or the like; and R7 is hydrogen or the like, or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same and uses for said compound/salt and composition. The compounds of the present invention exhibit potent dopamine D2 receptor simulating activities and thus are useful as a treating or preventing agent for Parkinson's disease and the like.

Abstract: The present invention provides compounds represented by the general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 is cyano or the like; R2 and R3 are hydrogen or the like; R4 is C1-6 alkyl or the like; R5 is C1-6 alkyl, halo-C1-6 alkyl, cycloalkyl, cycloalkyl-C1-6 alkyl, aralkyl or the like; R6 and R7 are each hydrogen, C1-6 alkyl, halo-C1-6 alkyl, cycloalkyl, C1-6 alkoxy-C1-6 alkyl, R12R13N—C1-6 alkyl or the like, which exhibit potent dopamine D2 receptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

Abstract: A storage unit stores rule information that includes information indicating a plurality of operations based on event data. A computing unit searches the rule information to find information indicating a first operation, information indicating an operation of a condition determination that is executable regardless of the result of the first operation, and information indicating a second operation that is associated with the condition determination and uses the result of the first operation. The computing unit generates control information for controlling the execution order of the operations such that the first operation is executed in accordance with the result of the condition determination and such that the second operation is executed after the first operation. When the event data is input, the computing unit executes an operation corresponding to the input event data, based on the control information.

Abstract: A non-transitory computer-readable medium including a program, which when executed by a computer, causes the computer to execute a process including collecting data item indicating specific criteria relating to a plurality of rules for gradually filtering a received data; and selectively extracting specific data relating to the collected data item indicating the specific criteria from content of the received data.

Abstract: A storage unit stores rule information that includes information indicating a plurality of operations based on event data. A computing unit searches the rule information to find information indicating a first operation, information indicating an operation of a condition determination that is executable regardless of the result of the first operation, and information indicating a second operation that is associated with the condition determination and uses the result of the first operation. The computing unit generates control information for controlling the execution order of the operations such that the first operation is executed in accordance with the result of the condition determination and such that the second operation is executed after the first operation. When the event data is input, the computing unit executes an operation corresponding to the input event data, based on the control information.

Abstract: The present invention relates to a method for producing an aramid core wire, containing a step of covering or impregnating an original yarn of an aramid core with a first treating agent containing a condensate of resorcin and formaldehyde, a latex and a water-soluble epoxy compound; an aramid core wire produced by the method; a transmission belt containing the aramid core wire; a method for producing the transmission belt; and a treating agent.

Abstract: In a wireless communication system based on a time division multiple access method such as cordless telephone systems including a door camera, voice communication is performed in a bi-directional communication by using a paired time slots, and image communication is performed in a uni-directional communication by using both of paired time slots. One of the paired time slots may be used for transmitting a control signal such as an image data resend control signal.

Abstract: The present invention provides compounds represented by the general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 is cyano or the like; R2 and R3 are hydrogen or the like; R4 is C1-6 alkyl or the like; R5 is C1-6 alkyl, halo-C1-6 alkyl, cycloalkyl, cycloalkyl-C1-6 alkyl, aralkyl or the like; R6 and R7 are each hydrogen, C1-6 alkyl, halo-C1-6 alkyl, cycloalkyl, C1-6 alkoxy-C1-6 alkyl, R12R13N—C1-6 alkyl or the like, which exhibit potent dopamine D2 receptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

Abstract: The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereo

Abstract: A camera diaphragm device in which two diaphragm blades, that is, first and second diaphragm blades having respective first and second diaphragm aperture portions whose diameters differ from each other is provided. The diaphragm blades are mounted to blade mounting shafts provided close to each other and in a standing manner, and are separately reciprocatingly rotated by driving pins of respective rotors. When the diaphragm device is set in a minimum diaphragm aperture control state, not only is the first diaphragm blade having the first aperture portion for restricting the minimum diaphragm aperture moved to an aperture portion, but also the second diaphragm blade having the second aperture portion for restricting an intermediate diaphragm aperture is moved to the aperture portion from the same direction. An area of the aperture portion that cannot be covered by only the first diaphragm blade is covered by the second diaphragm blade.

Abstract: An airbag device includes an airbag control IC constructed with a control signal generating circuit, a high-side switching element and a low-side switching element. Based on a signal for controlling the low-side switching element, on a signal for controlling a safety switching element and on a check mode signal, the control signal generating circuit adjusts the timing of the signal for controlling the high-side switching element so that the high-side switching element is turned on last. Therefore, the high-side switching element is turned on last. This suppresses the occurrence of an overshoot current.

Abstract: A camera diaphragm device in which two diaphragm blades, that is, first and second diaphragm blades having respective first and second diaphragm aperture portions whose diameters differ from each other is provided. The diaphragm blades are mounted to blade mounting shafts provided close to each other and in a standing manner, and are separately reciprocatingly rotated by driving pins of respective rotors. When the diaphragm device is set in a minimum diaphragm aperture control state, not only is the first diaphragm blade having the first aperture portion for restricting the minimum diaphragm aperture moved to an aperture portion, but also the second diaphragm blade having the second aperture portion for restricting an intermediate diaphragm aperture is moved to the aperture portion from the same direction. An area of the aperture portion that cannot be covered by only the first diaphragm blade is covered by the second diaphragm blade.

Abstract: A polyethylene-based stretched film with a thickness in the range of 10 to 100 ?m, the film comprising components (A) and (B) (the total amount of components (A) and (B) being 100 parts by weight), and has a density in the range of 898 to 960 Kg/m3: (A) 50 to 95 parts by weight of a polyethylene composition which comprises the following components (I) and (II) (the total amount of (I) and (II) being 100 parts by weight), and has a density in the range of 890 to 940 Kg/m3: (I) 5 to 95 parts by weight of an ethylene/alpha-olefin copolymer obtained by copolymerization of ethylene and an alpha-olefin having 4 to 12 carbon atoms with the use of a metallocene catalyst, which has a melt flow rate in the range of 0.

Abstract: The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 represents N or CR1; X2 represents N or CR2; X3 represents N or CR3; X4 represents N or CR4; and with the proviso that one or two of X1 to X4 represent N; R represents optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, etc.; R1 to R4 represent H, a halogen atom, etc.) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications, obesity or the like, pharmaceutical compositions comprising the same, and medicinal uses thereof.

Abstract: The present invention provides glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein P represents a hydrogen atom or a group forming a prodrug; R1 represents a hydrogen atom, an optionally substituted amino group, a carbamoyl group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, etc.; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkylthio group, etc., which have an improved oral absorption, and exert an inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, or pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.

Abstract: The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof

Abstract: The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts there

Abstract: The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.